Ketamine Bioavailability Explained: Why Sublingual Administration Matters

What Is Bioavailability and Why Does It Matter?

Bioavailability is a pharmacological term that describes the fraction of an administered drug that reaches systemic circulation in an active form. When a drug has 100% bioavailability, it means every molecule you take enters your bloodstream. Intravenous (IV) administration achieves 100% bioavailability by definition because the drug is delivered directly into the blood.

For ketamine tablets administered sublingually (under the tongue), bioavailability is significantly lower than IV but meaningfully higher than simply swallowing the medication. Understanding this concept helps explain why your clinician gives specific instructions about how to take your ketamine tablet and why following those instructions precisely affects your treatment outcomes.

The Two Pathways: Sublingual vs Oral (Swallowed)

When you place a ketamine tablet under your tongue, the drug can be absorbed through two distinct pathways, and the route it takes dramatically affects how much active ketamine reaches your brain.

Sublingual Absorption (The Preferred Route)

The tissue under your tongue (sublingual mucosa) is thin, highly vascularized, and permeable to many drugs. When ketamine dissolves and is absorbed through this tissue, it enters the venous blood supply that drains directly into the superior vena cava and then to the heart, bypassing the liver entirely. From the heart, ketamine-rich blood is pumped to the brain and throughout the body.

This pathway avoids what pharmacologists call "first-pass metabolism," which is the key advantage of sublingual administration.

Oral/GI Absorption (What Happens When You Swallow)

When dissolved ketamine is swallowed, whether intentionally or inadvertently with saliva, it travels through the esophagus to the stomach and small intestine. Ketamine is absorbed through the intestinal wall into the portal vein, which leads directly to the liver.

In the liver, enzymes (primarily CYP3A4 and CYP2B6) rapidly convert a substantial portion of ketamine into its metabolites, most notably norketamine. While norketamine does have some pharmacological activity, it is considerably less potent than ketamine itself for the therapeutic effects most patients are seeking.

This first-pass hepatic metabolism is the primary reason that swallowed ketamine has significantly lower bioavailability than sublingually absorbed ketamine.

The Numbers: How Much Difference Does It Make?

Published pharmacokinetic studies provide clear data on the bioavailability gap between sublingual and swallowed ketamine:

• Sublingual administration: Approximately 25-35% bioavailability
• Oral (swallowed) administration: Approximately 16-24% bioavailability

To put this in practical terms, if a patient takes a 100 mg ketamine tablet sublingually and achieves 30% bioavailability, approximately 30 mg of active ketamine reaches systemic circulation. If that same patient swallowed the 100 mg dose, only about 17-20 mg might reach the bloodstream as active ketamine.

That difference of 10-13 mg may sound small in absolute terms, but it represents a 35-45% reduction in the effective dose. For a treatment where dosing precision matters for both efficacy and safety, this variance is clinically significant.

Why Holding the Tablet Sublingually Is Critical

Given the bioavailability data, the instruction to hold your ketamine tablet under the tongue until it fully dissolves is not arbitrary. It is a direct application of pharmacokinetic science to maximize the therapeutic benefit of each dose.

The Dissolution Window

Most sublingual ketamine tablets are designed to dissolve within 5 to 10 minutes. During this period, ketamine is continuously released from the dissolving tablet and absorbed through the sublingual mucosa. The longer the drug remains in contact with the sublingual tissue, the more ketamine enters the bloodstream via the preferred (non-hepatic) route.

The Saliva Challenge

As the tablet dissolves, it mixes with saliva. The natural swallowing reflex means that some of this ketamine-laden saliva will inevitably be swallowed. This is normal and expected; clinicians account for some oral absorption when determining your dose. However, minimizing unnecessary swallowing during the dissolution period preserves more of the sublingual absorption advantage.

Practical tips for maximizing sublingual absorption:

• Tilt your head slightly forward to allow saliva to pool under the tongue rather than draining toward the throat
• Resist the urge to swallow for as long as comfortably possible during the dissolution period
• Avoid talking while the tablet is dissolving, as jaw and tongue movement can shift the tablet and stimulate swallowing
• Do not eat or drink for at least 15 minutes before and after administration to maintain optimal mucosal conditions

After Full Dissolution

Some clinicians instruct patients to hold the remaining saliva under the tongue for an additional 2 to 5 minutes after the tablet has fully dissolved, then spit out the residual saliva. Others advise patients to simply swallow at that point. Follow your specific clinician's instructions, as they have calibrated your dose with their recommended administration protocol in mind.

Factors That Affect Individual Bioavailability

Even among patients who follow sublingual administration instructions perfectly, bioavailability varies from person to person. Several physiological factors influence how much ketamine each individual absorbs.

Oral Mucosa Health

The sublingual tissue must be intact and healthy for optimal absorption. Conditions that can reduce absorption include:

• Oral mucositis or ulcers
• Dry mouth (xerostomia), which reduces the dissolution medium
• Recent oral surgery or dental procedures
• Chronic tobacco use, which can thicken mucosal tissue

Saliva pH and Composition

Ketamine is a weak base with a pKa of 7.5. The pH of saliva (typically 6.2-7.6) affects the ionization state of ketamine, which in turn influences its ability to cross mucosal membranes. The un-ionized form of a drug crosses biological membranes more readily than the ionized form.

When salivary pH is closer to or above 7.5, a greater proportion of ketamine molecules are in the un-ionized state, potentially improving absorption. This is one reason some compounding pharmacies adjust the pH of their formulations.

Blood Flow to the Sublingual Area

Greater blood flow to the sublingual mucosa means faster removal of absorbed ketamine from the tissue, maintaining a favorable concentration gradient that drives further absorption. Factors that reduce local blood flow, such as vasoconstricting medications or cold temperatures, could theoretically reduce absorption rates.

Body Weight and Composition

While body weight does not directly affect bioavailability (the percentage absorbed), it does influence the plasma concentration achieved from a given absorbed dose. This is why clinicians often calculate ketamine doses on a per-kilogram basis and adjust based on individual response.

Norketamine: The Primary Metabolite

When ketamine undergoes first-pass metabolism, it is primarily converted to norketamine (also called N-desmethylketamine). Understanding norketamine helps explain why swallowed ketamine still produces some therapeutic effects, even with lower parent drug bioavailability.

Norketamine retains approximately one-third of the anesthetic potency of ketamine and does interact with NMDA receptors, though less potently. Some researchers have investigated whether norketamine contributes to the antidepressant effects of ketamine, but the evidence currently suggests that the parent compound (ketamine) and its rapid effects on glutamate signaling are the primary drivers of the antidepressant response.

This means that even though swallowed ketamine produces more norketamine relative to parent ketamine, the therapeutic trade-off is not favorable. The goal remains to maximize parent ketamine absorption through sublingual delivery.

How Clinicians Account for Bioavailability in Dosing

Your prescribing clinician uses published bioavailability data, along with your individual response, to determine the appropriate tablet dose. The dose written on your prescription already factors in the expected sublingual bioavailability.

For example, if a clinician wants to achieve a systemic exposure roughly equivalent to a 0.5 mg/kg IV dose in a 70 kg patient (35 mg IV), they might prescribe a sublingual dose of approximately 100-150 mg, knowing that only 25-35% will reach systemic circulation.

This is why patients should never compare their sublingual dose directly to IV doses or to other patients' doses without understanding the bioavailability context. A "higher" sublingual dose does not mean a "stronger" treatment; it reflects the pharmacokinetic reality of the administration route.

Comparing Routes of Administration

For context, here is how ketamine bioavailability compares across common clinical routes:

Each route has its own clinical context, advantages, and limitations. Sublingual tablets offer a practical balance of reasonable bioavailability with the convenience of at-home self-administration under clinical supervision.

Emerging Research on Improving Oral Bioavailability

Pharmaceutical researchers are actively working on formulations that could increase the bioavailability of oral ketamine. Approaches under investigation include:

• Permeation enhancers: Excipients that temporarily increase the permeability of the oral mucosa
• Mucoadhesive formulations: Tablets or films that adhere to the sublingual tissue, prolonging contact time
• Nanoparticle delivery systems: Engineered particles that improve drug transport across mucosal barriers
• Prodrug approaches: Modified ketamine molecules that resist hepatic metabolism and convert to active ketamine after absorption

These technologies are at various stages of development and may eventually offer patients improved absorption without changing the fundamental convenience of oral administration.

Summary

Bioavailability is not an abstract pharmacological concept; it directly determines how much benefit you receive from each ketamine tablet. By understanding why sublingual absorption outperforms swallowed administration and by following your clinician's instructions for proper tablet placement and dissolution, you can help ensure that your treatment delivers its intended therapeutic effect.

If you have questions about your specific dosing or administration technique, bring them to your next appointment. Your clinician can provide personalized guidance based on your treatment response and individual physiology.

References

• Pharmacokinetics of Ketamine in Humans After IV, IM, and Oral Administration — Comprehensive pharmacokinetic study measuring ketamine bioavailability across multiple routes
• First-Pass Metabolism of Ketamine: Role of CYP3A4 and CYP2B6 — Research on the hepatic enzymes responsible for ketamine metabolism
• Sublingual and Buccal Drug Delivery — Review of sublingual absorption mechanisms and factors affecting drug bioavailability
• Norketamine: Pharmacological Properties and Clinical Significance — Analysis of norketamine's pharmacological activity relative to parent ketamine
• NIH National Institute of Mental Health — Ketamine Research — NIMH resources on ketamine and mental health treatment research